|
Aiko's patented portfolio of compounds includes naltrexone / naloxone analogs, including naltrexol, naltrexamine and naloxol derivatives. Each compound has been demonstrated to display neutral antagonist properties at the mu opioid receptor.
| |
AIKO Biotechnology steps back to reformulate, seek financing
Reported in Mass High Tech
Aiko Biotechnology Inc., a Portland, Maine, company focused on drug candidates to relieve the side effects from long-term prescription opioid pain reliever use, is taking a step back to reformulate its lead compound from an injectable into a pill.
At the same time, it is seeking both a partner to infuse money and resources and $10 million in private-placement funding to advance its early-stage drug programs, according to CEO Jim New, who joined the company last September as it moved from its scientific founders into a professional management phase.
Read the complete story in Mass High Tech
|
